New simultaneous lung-kidney allocation policy benefits adult recipients of lung transplant with chronic renal dysfunction Authors: Reed Jenkins, Jiashu Xue, Jessica Ruck, Al-Faraaz Kassam, Hamid Rabb, Christian Merlo, Errol Bush Published: 2026 ABSTRACT AbstractObjectiveThe United Network for Organ Sharing defined allocation policies for Simultaneous Lung-Kidney transplantation (SLK) in 2023. However, SLK has rarely been performed, and the benefit for lung transplant candidates remains unclear. We sought to determine the outcomes for lung transplant recipients (LTRs) with pretransplant renal dysfunction and estimate the potential impact of the policy.MethodsUsing Organ Procurement and Transplantation Network data, we categorized adult LTRs from 2005 to 2022 by pretransplant renal dysfunction. We then retrospectively applied the 2023 SLK eligibility criteria to identify LTRs with kidney dysfunction who would have been eligible for SLK. Next, we evaluated the outcomes for SLK-eligible LTRs who received SLK or lung transplant using adjusted Cox regression.ResultsAmong 17,954 LTRs, 1913 (10.7%) had pretransplant renal dysfunction. Applying the new OPTN SLK allocation policy to the retrospective cohort, 292 (16.2%) LTRs would have been eligible for SLK, and 39 LTRs received SLK. SLK recipients had significantly greater pretransplant dialysis use (69% vs 34%, P < .01) and greater lung allocation score (85 vs 51, P < .001). Yet, 3-year overall (81% vs 58%, P < .001) and adjusted (adjusted hazard ratio, 0.30; 95% CI, 0.13-0.68; P = .004) survival was significantly improved among SLK versus LT-only recipients. The risk of all-cause graft loss for SLK recipients was 76% lower compared with lung-only recipients (adjusted hazard ratio, 0.24; 95% CI, 0.11-0.54; P = .001).ConclusionsIn the historical cohort, a minority of LTRs who were eligible for SLK by contemporary Organ Procurement and Transplantation Network criteria received a multiorgan transplant. However, despite being sicker, recipients of SLK had significantly improved survival compared with candidates eligible for SLK who received lung-only transplants.Key Words: simultaneous lung-kidney transplantation, multiorgan transplant, lung transplantation for recipients with renal dysfunction, multiorgan allocation, lung transplant Number of simultaneous lung-kidney (SLK) transplantations by year (2005-2022). Central Message LTRs who were SLK-eligible by new UNOS criteria and received a multiorgan transplant had significantly improved survival compared with those who had lung-only transplants. Perspective UNOS defined allocation policies for simultaneous lung-kidney (SLK) transplantation in 2023. However, SLK has rarely been performed, and the benefit for lung transplant candidates remains unclear. Given the demonstrated survival benefit in SLK-eligible recipients, this policy change could have an outsized impact on lung transplant recipients with concomitant kidney dysfunction. Simultaneous lung-kidney transplantation (SLK) has emerged as a strategy to address inferior posttransplant outcomes in lung transplant recipients (LTRs) with serious kidney dysfunction. Although a small minority of candidates for lung transplantation have pre-existing kidney dysfunction, poor pretransplant renal function is strongly associated with posttransplant kidney dysfunction, need for dialysis, and increased posttransplant mortality for LTRs.1, 2, 3 Despite the connections between pretransplant kidney dysfunction and posttransplant outcomes, the use of SLK in the United States has historically been scarce, with a total of 99 SLK transplants performed nationwide from 1995 to 2021.4,5 However, in 2022, the Organ Procurement and Transplantation Network (OPTN) codified policies for multiorgan allocation, which formalized criteria for SLK transplantation. Before the policy change, candidates for lung transplant (LT) could receive a simultaneous kidney transplant from the same donor if they were simultaneously listed for both lung and kidney transplants, but there were not clear guidelines stipulating when organ procurement organizations should offer a second organ to these candidates.6 The clarified guidelines stipulated that candidates for LTs with a lung allocation score (LAS) >35 and simultaneous listing on the kidney transplant list could receive SLK offers when allocating according to the lung match run and located within 500 nautical miles of the donor hospital.6,7 In September of 2023, the allocation criteria for SLK were further updated, mandating lung-kidney allocation from the same donor to lung candidates with demonstrated kidney dysfunction, including either chronic kidney disease (CKD) with a measured or estimated glomerular filtration rate (eGFR) ≤60 mL/min for greater than 90 consecutive days or sustained acute kidney injury, demonstrated by the need for dialysis or an eGFR <25 at least once per week for 6 weeks.7 By enacting these changes, OPTN clarified multiorgan allocation policy and established SLK as an important option for recipients with kidney dysfunction. Despite the recent formalization of SLK policy by OPTN, there are limited data on outcomes for recipients of SLK. In a small retrospective sample of 31 recipients of SLK from 1995 to 2013, Reich and colleagues4 found similar short- and long-term outcomes compared with lung-only transplants. More recent SLK data have shown a survival benefit of SLK over lung-only transplant in candidates requiring pretransplant dialysis or with an eGFR <30 mL/min.5 However, given the recent updates to multiorgan allocation policy, it is not known how many historical LTRs would have been eligible for SLK and whether SLK would have provided a survival benefit compared with lung-only transplant in this cohort. In this study, we sought to evaluate the potential benefit of SLK compared with lung-only transplant for lung candidates with pretransplant kidney dysfunction by retroactively applying the new OPTN SLK allocation criteria to historical candidates for LT and identifying candidates for LT in the LAS era (2005-2022) who would have potentially qualified for SLK. We then aimed to delineate whether historical candidates eligible for SLK who received SLK had improved outcomes compared with lung-only recipients. We hypothesized that SLK would provide a survival benefit compared with lung-only transplant for these recipients. Methods Data Source This study used data from the OPTN. The OPTN data system includes data on all donors, wait-listed candidates, and transplant recipients in the United States, submitted by the members of the OPTN. The Health Resources and Services Administration, US Department of Health and Human Services provides oversight to the activities of the OPTN and OPTN contractors. These data have been described elsewhere.8 In OPTN/Scientific Registry of Transplant Recipients, mortality and graft loss are reported by individual transplant centers, and ascertainment is supplemented through linkage to the Social Security Master Death File (mortality) and the waiting list (graft loss). This study was deemed exempt for the need for institutional review board approval by the Johns Hopkins Institutional Review Board (NA_00042871). Consent was not required. Study Population Using OPTN data between May 2005 and January 2023, we identified all 17,954 adult (≥18 year old) first-time LTRs with calculated LAS score >35 at listing. All transplants occurred before the advent of the lung composite allocation score. SLK transplants were included, whereas all other multiorgan transplants (eg, simultaneous lung-heart, lung-liver) were excluded (N = 662). A subset of all LTRs who would have been eligible for SLK were retrospectively identified using the new Simultaneous Lung-Kidney allocation policy criteria (candidate with LAS >35, chronic dialysis regularly or any eGFR <30 mL/min between listing and transplant).9 This subset of LTRs either received SLK (N = 39) or lung-only transplant (N = 253). Recipients that were re-transplants or had a previous lung transplant were excluded. Donor, Recipient, and Transplant Characteristics We compared the donor, recipient, and transplant characteristics of SLK transplants and lung-only transplants using χ2 and Wilcoxon rank-sum testing. We empirically included donor age, sex, body mass index (BMI), type (donation after brain death vs donation after circulatory death), and smoking history (≥20 vs <20 pack-years); recipient age, sex, race, ethnicity, BMI, pretransplant dialysis, lung-transplant diagnosis group (obstructive, pulmonary vascular, cystic fibrosis and immunodeficiency, and restrictive lung disease) cold ischemia time (hours), diabetes and LAS; and the type of lung transplant (unilateral vs bilateral) as covariables in our multivariable model. Of the empirically included covariates, only donor smoking history had missing values (N = 325), and these patients were excluded. Within our study period, years of transplant were centered at 2006 (when the first SLK since the institution of LAS was performed) and adjusted in the model as a continuous variable to account for temporal changes in transplant practice and outcomes. Pretransplant Renal Dysfunction We identified the severity of renal dysfunction for LTRs at lung transplant by National Institute of Diabetes and Digestive and Kidney Diseases chronic kidney disease (CKD) level using the serum creatinine measurements between listing and LT.10,11 We used Chronic Kidney Disease Epidemiology Collaboration, CKD-EPI_2009 calculation.12, 13, 14 The lowest renal function follow-up data during listing was used for CKD classification. LTRs were classified into stage I and II (normal renal group); stage III, stage IV, and stage V (renal dysfunction group) at LT. Risk of Pretransplant Renal Dysfunction in Recipients of Lung-Only Transplantation We identified lung-only recipients of transplantation and compared 3-year posttransplant mortality between LTRs with renal dysfunction and LTRs with normal renal function. We sought to quantify the association between pre-lung transplant renal function and posttransplant outcomes using multivariable Cox proportional hazard function with the empirically included covariates and univariate statistically significant variables. We also used log-rank tests and Kaplan-Meier curves for a crude hazard ratio. LTRs were followed from the date of LT surgery until the outcome of interest or administrative censorship on January 1, 2023. Characterization of the SLK Transplant Landscape To determine historical trends for SLK transplants in centers across the United States, we counted the number of SLKs performed per year since 2005. Applying the new SLK policy, we also identified the potential candidates eligible for SLK listed by year. To determine whether SLK occurred at a few centers or were more widespread, we plotted Lorenz curves and calculated the Gini coefficient, a dimensionless statistic ranging from 0 to 1. In this study context, a Gini coefficient near 1 indicated that few centers performed nearly all SLK transplants in the country. We compared the Gini index for 2005-2017 with 2018-2023, because 2018 was the first year that the number of SLK transplants exceeded 50% of SLK-listed candidates. Impact of SLK Practice in Candidates Eligible for SLK To determine the potential impact of SLK practice under the new policy criteria, we applied the 2023 SLK allocation policy criteria to a historic cohort of candidates for LT. We identified candidates who were eligible for SLK, and then we compared 3-year posttransplant mortality and all-cause graft loss (ACGL; ACGL is the composite of mortality and graft failure) among candidates who were eligible for SLK and received lung-kidney versus lung-only transplants. We quantified the association of SLK practice and transplant outcomes in the candidates who were eligible for SLK under the new policy using a multivariable Cox proportional hazard function with the empirically included covariates. LTRs who would have been potentially eligible for SLK transplant, yet received lung-only transplant, were censored at the time of kidney transplantation if they subsequently received a kidney transplant after being on the kidney transplant waitlist. Statistical Analyses Analyses were performed using Stata/SE, version 18 (Stata Corp). We used a 2-sided alpha of 0.05 to indicate a statistically significant difference. As a sensitivity analysis, we examined the death-censored graft failure as an additional outcome. We also performed multilevel modeling to account for center-level clustering and compared the Gini index before and after 2018. We then examined the time era difference and robustness by comparing the model with and without adjusting year-of-transplant factors using a likelihood ratio test. Results Study Population and Recipient Characteristics Of the 17,954 adult LTRs included, 1913 (10.7%) had pretransplant renal dysfunction; of those, 1314 (68.7%), 75 (3.9%), and 23 (1.2%) had stage III, IV, and V renal failure respectively. Compared with LTRs from the normal renal function group, LTRs from the pretransplant renal dysfunction group were older (median, 63 vs 60 years; P < .001); more likely to be female (44% vs 34%, P < .001); and had a greater median BMI (median 27.3 vs 25.9, P < .01). Recipients with renal dysfunction also had a greater likelihood of pulmonary vascular lung disease (12.5% vs 4.1%; P < .001), a greater likelihood of dialysis before transplant (3.0% vs 0.0%; P < .001), a greater likelihood of diabetes (25.9% vs 23.6%; P = .026), and increased median LAS at transplant (median 43 vs 32, P < .01) (Table 1). Table 1Recipient and donor characteristics of lung-only transplants (LT) for the pretransplant renal dysfunction group versus normal renal function groupFactorNo pre-LT renal dysfunction (n = 16,041)Pre-LT renal dysfunction (n = 1913)P valueWaitlist time, y, median (IQR)0.07 (0.02, 0.21)0.07 (0.02, 0.19).39Sex, female5492 (34.2%)845 (44.2%)<.001Age, median (IQR)60 (51, 66)63 (57, 68)<.001Race<.001 White12,125 (75.6%)1533 (80.1%) Black1551 (9.7%)195 (10.2%) Hispanic1744 (10.9%)130 (6.8%) Other621 (3.9%)55 (2.9%)BMI, median (IQR)26 (22, 29)27 (24, 30)<.001Diabetes3767 (23.6%)493 (25.9%).026Primary insurance type<.001 Private8059 (50.2%)875 (45.7%) Public7801 (48.6%)1027 (53.7%) Other181 (1.1%)11 (0.6%)On life support at time of transplant2125 (13.3%)293 (15.3%).014Recipient diagnosis<.001 Obstructive1262 (7.9%)157 (8.2%) Pulmonary vascular659 (4.1%)240 (12.5%) CF and Immunodeficiency1688 (10.5%)90 (4.7%) Restrictive12,363 (77.1%)1412 (73.8%) Other69 (0.4%)14 (0.7%)Lung allocation score, median (IQR)42.27 (37.98, 52.35)43.40 (38.26, 54.10).001ECMO at listing519 (3.2%)79 (4.1%).043ECMO at transplant1049 (6.5%)144 (7.5%).11On ventilator at time of transplant1175 (7.3%)156 (8.2%).20Dialysis b/t listing and transplant0 (0.0%)57 (3.0%)<.001Ischemic time, h, median (IQR)5.30 (4.27, 6.45)5.35 (4.32, 6.55).26EVLP used362 (2.3%)43 (2.2%)>.99CMV donor+/recipient−4245 (26.5%)516 (27.0%).64Donor factors Sex, female6671 (41.6%)869 (45.4%).001 Blood type.44 O8321 (51.9%)969 (50.7%) A5633 (35.1%)677 (35.4%) B1746 (10.9%)217 (11.3%) AB341 (2.1%)50 (2.6%) Age, y, median (IQR)33 (23, 46)33 (23, 47).47 Race.006 White9454 (58.9%)1185 (61.9%) Black3014 (18.8%)369 (19.3%) Hispanic2891 (18.0%)292 (15.3%) Other682 (4.3%)67 (3.5%) BMI, median (IQR)26 (23, 29)26 (23, 29).20 Smoking history (>20 pack-years)1282 (8.1%)149 (8.0%).86 Donation after circulatory death627 (3.9%)64 (3.3%).26IQR, Interquartile range; BMI, body mass index; CF, cystic fibrosis; ECMO, extracorporeal membrane oxygenation; EVLP, ex vivo lung perfusion; CMV, cytomegalovirus. Recipient and donor characteristics of lung-only transplants (LT) for the pretransplant renal dysfunction group versus normal renal function group IQR, Interquartile range; BMI, body mass index; CF, cystic fibrosis; ECMO, extracorporeal membrane oxygenation; EVLP, ex vivo lung perfusion; CMV, cytomegalovirus. Of the 292 recipients identified as eligible for SLK under the new policy, 13.4% (39/292) received SLK transplants. Compared with recipients eligible for SLK who underwent lung-only transplant, SLK recipients were younger (median, 50 vs 56 years; P < .001), more likely to be Black or African American (20.5% vs 11.5%; P < .003); had greater rates of pretransplant dialysis (69% vs 34%, P < .01); had an increased prevalence of diabetes (44% vs 25%, P < .021), and had greater LAS at transplant or match (median 85 vs 51, P < .001) (Table 2). Table 2Recipient and donor characteristics for SLK-eligible recipients: SLK versus lung-only transplantsFactorLung-onlyn = 253Lung-kidneyn = 39P valueRecipient factors Waitlist time, y, median (IQR)0.05 (0.02, 0.14)0.07 (0.02, 0.12).84 Sex, female104 (41.1%)13 (33.3%).39 Age, median (IQR)56 (44, 64)50 (37, 55)<.001 Race.003 White193 (76.3%)19 (48.7%) Black29 (11.5%)8 (20.5%) Hispanic24 (9.5%)10 (25.6%) Other7 (2.8%)2 (5.1%) BMI, median (IQR)26 (22, 30)24 (21, 29).12 Diabetes60 (25.2%)17 (43.6%).021 Primary payment insurance.50 Private153 (60.5%)22 (56.4%) Public94 (37.2%)17 (43.6%) On life support at time of transplant98 (39.4%)14 (35.9%).73 Diagnosis.43 Obstructive20 (7.9%)3 (7.7%) Pulmonary vascular26 (10.3%)4 (10.3%) CF and immunodeficiency35 (13.8%)10 (25.6%) Restrictive171 (67.6%)22 (56.4%) Lung allocation score, median (IQR)50.81 (40.46, 79.62)85.41 (55.93, 90.27)<.001 ECMO at listing43 (17.0%)11 (28.2%).12 ECMO at transplant60 (23.7%)12 (30.8%).33 Ventilator at time of transplant72 (28.5%)8 (20.5%).34 Dialysis b/t listing and transplant61 (33.7%)27 (69.2%)<.001 Ischemic time, h, median (IQR)5.88 (4.63, 7.00)5.15 (4.30, 6.02).064 CMV donor+/recipient−53 (20.9%)11 (28.2%).30Donor factors Sex, female117 (46.2%)15 (38.5%).39 Blood type.78 O128 (50.6%)19 (48.7%) A91 (36.0%)15 (38.5%) B28 (11.1%)5 (12.8%) AB6 (2.4%)0 (0.0%) Age, y, median (IQR)34 (24, 47.00)28 (21, 43).10 Race.34 White162 (64.0%)25 (64.1%) Black51 (20.2%)5 (12.8%) Hispanic36 (14.2%)7 (17.9%) Other4 (1.6%)2 (5.1%) BMI, median (IQR)26 (22, 29)24 (21, 25).015 Donor smoking history (>20 pack-years)27 (10.8%)3 (7.7%).78 Donation after circulatory death8 (3.2%)0 (0.0%).60SLK, Simultaneous lung-kidney transplantation; IQR, interquartile range; BMI, body mass index; CF, cystic fibrosis; ECMO, extracorporeal membrane oxygenation; CMV, cytomegalovirus. Recipient and donor characteristics for SLK-eligible recipients: SLK versus lung-only transplants SLK, Simultaneous lung-kidney transplantation; IQR, interquartile range; BMI, body mass index; CF, cystic fibrosis; ECMO, extracorporeal membrane oxygenation; CMV, cytomegalovirus. Outcomes of Lung-Only Recipients With Pretransplant Renal Dysfunction Comparing lung-only recipients with pretransplant renal dysfunction with recipients with normal renal function, the renal dysfunction group had lower survival (64% vs 74% P < .01) and lower all-cause graft survival (64% vs 74% P < .01) at 3 years (Figure 1, Figure E1). The risk of mortality at 3 years posttransplant was 1.39 times greater for LTRs with renal dysfunction (adjusted hazard ratio [aHR], 1.39; 95% CI, 1.19-1.63; P < .001) (Table 3). Comparison of 3-year lung-only recipient posttransplant survival with and without pretransplant renal dysfunction. Shaded areas indicate 95% CI. LT, lung transplantation; HR, hazard ratio. Three-year posttransplant all-cause graft loss among recipients with pre-transplant renal dysfunction and normal renal function. LT, Lung transplantation; HR, hazard ratio. Table 3Multivariable Cox regression model for 3-year mortality risk factors stratified by pretransplant renal dysfunctionaHR95% CIP valueRecipient variablePre-LT renal dysfunction1.391.19-1.63<.001Sex, female0.900.84-0.97.004Race Whiteref Black1.111.00-1.22.040 Hispanic0.890.80-0.99.025 Other0.880.74-1.04.132Age1.011.00-1.01<.001BMI1.011.00-1.01.204Diabetes1.051.00-1.14.222Insurance type PrivateRef Public1.091.03-1.16.004 Other0.740.54-1.02.064On life support1.000.88-1.15.981Diagnosis Pulmonary vascular1.070.91-1.26.428 CF and immunodeficiency0.980.83-1.16.847 Restrictive0.940.85-1.05.313 Other0.990.66-1.50.977Lung allocation score1.011.00-1.01.001ECMO at transplant1.060.91-1.24.464On ventilator1.251.07-1.47.005Renal stage Normal renal stageRef Stage 3A0.920.76-1.05.412 Stage 3B0.950.69-1.08.718 Stage 42.061.43-2.98<.001 Stage 50.970.56-1.96.918Ischemia (hour)1.010.99-1.03.243CMV mismatch (D+/R−)1.131.07-1.19<.001Donor variable Race Whiteref Black1.281.18-1.38<.001 Hispanic1.091.00-1.18.041 Other1.201.04-1.38.015 Age1.011.00-1.01.000 BMI0.990.98-0.88<.001 Smoking status1.191.07-1.31.001 Sex, female1.060.99-1.13.086 Donation after circulatory death1.080.92-1.26.322aHR, Adjusted hazard ratio; LT, lung transplantation; CF, cystic fibrosis; ECMO, extracorporeal membrane oxygenation; CMV, cytomegalovirus; BMI, body mass index. Multivariable Cox regression model for 3-year mortality risk factors stratified by pretransplant renal dysfunction aHR, Adjusted hazard ratio; LT, lung transplantation; CF, cystic fibrosis; ECMO, extracorporeal membrane oxygenation; CMV, cytomegalovirus; BMI, body mass index. Landscape of SLK Transplant Before the Policy Update From May 2005 to January 2023, a total of 67 SLK transplants were performed, with single-digit cases (<10) performed before 2016 (Figure 2, A). Using the new OPTN policy eligibility criteria, 292 LTRs would have potentially been eligible for SLK, but only 39 of those received SLK in practice. However, both the number of SLKs and the proportion of recipients eligible for SLK receiving an SLK increased over the study period (Figure 2, B). The Gini index for receiving an SLK for eligible LTRs was 0.913 in the 2005-2017 era and 0.747 in the post-2018 era, suggesting that SLKs were more widely and evenly distributed across transplant centers in recent years (Figure E2). A, Number of simultaneous lung-kidney (SLK) transplantations.by year (2005-2022). B, Number of SLK and new SLK-eligible candidates listed for lung transplant (2005-2022). Lorenz curve for centers performing simultaneous lung-kidney transplantations. LTR, Lung transplant recipient. Outcomes of SLK Transplants in the Historical SLK-Eligible Group In the historical SLK-eligible cohort, 3-year survival was significantly greater in candidates who received SLK compared with lung-only recipients (81% vs 58%, P < .001, Figure 3). In addition, the risk of mortality for SLK recipients was 70% lower compared with lung-only recipients after adjusting for donor, recipient, and transplant characteristics (aHR, 0.30; 95% CI, 0.13-0.68; P = .004) (Table 4). The risk of ACGL for SLK recipients was 74% lower compared with lung-only recipients after adjusting for donor, recipient, and transplant characteristics (aHR, 0.26; 95% CI, 0.11-0.59; P = .001) (Table 5). Three-year posttransplant patient survival among simultaneous lung-kidney-eligible recipients. Shaded areas indicate 95% CI. LT, Lung transplantation; HR, hazard ratio. Table 4Multivariable Cox regression for 3-year mortality by risk factor comparing SLK versus lung-only recipientsaHR95% CIP valueRecipient variable Received lung-kidney0.300.13-0.68.004 Age1.031.00-1.05.002 Sex, female2.201.28-3.78.004 Diabetes1.060.62-1.81.967 Diagnosis Obstructiveref Pulmonary vascular0.460.14-1.51.201 CF and immunodeficiency1.490.48-4.57.486 Restrictive0.640.27-1.52.031 Other1.140.15-8.87.898 Lung allocation score1.011.00-1.03.060 ECMO at transplant0.580.28-1.19.139 Dialysis pretransplant2.081.13-3.81.018 Ischemia (hours)1.141.01-1.30.043 CMV mismatch (D+/R−)1.030.54-1.60.794Donor variable BMI1.020.98-1.05.349 Smoking status0.980.46-2.08.953 Sex, female1.160.71-1.91.555 Donation after circulatory death0.630.15-2.69.534SLK, Simultaneous lung-kidney transplantation; ECMO, extracorporeal membrane oxygenation; CMV, cytomegalovirus; BMI, body mass index. Multivariable Cox regression for 3-year mortality by risk factor comparing SLK versus lung-only recipients SLK, Simultaneous lung-kidney transplantation; ECMO, extracorporeal membrane oxygenation; CMV, cytomegalovirus; BMI, body mass index. Table 5Multivariable Cox regression model for 3-year all-cause graft loss risk factor by receiving lung-kidney versus lung-onlyaHR95% CIP valueRecipient variable Received lung-kidney0.260.11-0.59.001 Sex, female1.931.13-3.28.015 Age1.031.00-1.05.020 Diabetes1.070.64-1.79.797 Diagnosis Obstructiveref Pulmonary vascular0.510.15-1.67.267 CF and immunodeficiency1.850.62-5.50.266 Restrictive0.730.31-1.71.467 Other1.080.14-8.34.940 Lung allocation score1.011.00-1.03.097 ECMO at transplant0.630.32-1.26.189 Dialysis pretransplant2.271.26-4.07.006 Ischemia (hours)1.120.99-1.27.071 CMV mismatch (D+/R−)0.950.57-1.60.852Donor variable BMI1.010.98-1.05.428 Smoking status0.930.48-2.06.990 Sex, female1.170.72-1.90.525 Donation after circulatory death0.590.14-2.48.468aHR, Adjusted hazard ratio; CF, cystic fibrosis; ECMO, extracorporeal membrane oxygenation; CMV, cytomegalovirus; BMI, body mass index. Multivariable Cox regression model for 3-year all-cause graft loss risk factor by receiving lung-kidney versus lung-only aHR, Adjusted hazard ratio; CF, cystic fibrosis; ECMO, extracorporeal membrane oxygenation; CMV, cytomegalovirus; BMI, body mass index. Statistical Analyses In the sensitivity analysis, the risk of death-censored graft failure for lung-kidney recipients was 71% lower compared with lung-only recipients with the same adjustment (aHR, 0.29; 95% CI, 0.10-0.56; P = .001). All results remained consistent with and without the adjustment of transplant year centered on 2006, and center-level bias. Discussion Our study used retrospective national registry data to evaluate the landscape of SLK in the United States after the recent enactment of a comprehensive multiorgan allocation policy by OPTN in late 2023. In the study period, from 2005 to 2022, we found that SLK was rarely used, with only 13.8% of recipients we found to be eligible for SLK by the 2023 criteria receiving a multiorgan transplant. However, despite being sicker, with greater LAS and dialysis use, candidates who received SLK had significantly improved survival compared with those who received a lung-only transplant, with a 3-year survival of 81% compared with 58% in the LT-only group, accentuating the potential impact of the new policy. Recipients of SLK received clear benefits in mortality and graft survival. Compared with recipients with pretransplant renal function who only received a lung transplant, recipients of SLK had a 76% risk reduction for ACGL and a 73% reduction in mortality risk. Recipients also had significantly improved 3-year survival. Experience with SLK from the United States and around the world is limited, with only 2 cohort studies, 1 single-center retrospective study, and several case reports comprising the extant literature.5,15,16 Results from these studies show similar short-term survival as well as promising long-term outcomes. However, the global sample size is limited, with fewer than 200 total SLK reported. Our study is the first to directly compare recipients of SLK with LT-only recipients with kidney dysfunction that would now qualify them for SLK. The improved survival in the SLK cohort emphasizes the benefit of the practice and highlights the necessity of careful screening in this population for SLK eligibility. As the numbers of SLK performed increase, further study is needed to fully quantify the benefits of SLK for selected recipients. Despite the prevalence of kidney dysfunction in candidates for LT, SLK was rarely performed until recent years, with fewer than 5 SLKs per year until 2017. From 2017 onwards, the prevalence of SLK has increased, with 13 SLKs in both 2021 and 2022. However, despite these increases, data from the historical cohort also show the relative underuse of SLK, with only 13.8% of retrospectively eligible candidates receiving SLK. With the recent OPTN policy changes formalizing criteria for SLK eligibility, it is likely that SLK rates will continue to increase. However, along with a renewed interest in SLK has come “rescue” kidney policies aimed at salvaging kidney function in lung LTRs up to a year posttransplant. There is a paucity of data comparing outcomes for SLK and rescue kidney recipients, with only 1 small single-center retrospective cohort trial showing equivalent short-term outcomes.16 Further study is needed to contrast the 2 modalities and identify the ideal recipients for each. With implementation of the policy, we expect the SLK practice case to increase, and an assessment of center-level and United Network for Organ Sharing regional-level variation would be necessary for the future follow-up study. This study was limited by the application of current SLK eligibility criteria to a retrospective national cohort, with its inherent lack of granularity. Specifically, we were unable to determine the etiology of kidney dysfunction in recipients or use ancillary diagnostic data, including urinalysis or kidney biopsy, which are absent from the database. The nature of the available data makes it possible that some candidates may have wrongly been characterized as eligible for SLK. Conversely, our data may also potentially underestimate the number of recipients with significant kidney dysfunction because many LTRs are sarcopenic, potentially leading to falsely high eGFR.16 Because our data only include transplants through 2022, we did not capture the impacts of the new OPTN policy on SLK trends, which necessitates further exploration. Before the formalization of recipient eligibility for SLK allocation in 2023, SLK was significantly underused. Given the demonstrated survival benefit in recipients eligible for SLK, this policy change could have an outsized impact on LTRs with concomitant kidney dysfunction. We look forward to seeing the impacts of this policy on the number of SLK transplants in coming years as well as long-term survival in this subpopulation of candidates. Conflict of Interest Statement The authors reported no conflicts of interest. The Journal policy requires editors and reviewers to disclose conflicts of interest and to decline handling or reviewing manuscripts for which they may have a conflict of interest. The editors and reviewers of this article have no conflicts of interest. Footnotes This research has been supported by the National Institute on Aging (F32AG067642, to Dr Ruck). Drs Jenkins and Xue contributed equally to this article. Appendix E1 References